Keyphrases
Circulating Tumor Cells
100%
Taxanes
100%
Treatment Outcome
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Hormonal Treatment
100%
Multicenter Cohort Study
100%
Androgen Receptor Splice Variant 7
100%
Enzalutamide
55%
Abiraterone
55%
Overall Survival
55%
Hazard Ratio
44%
Taxane Chemotherapy
44%
Radiological Response
22%
Johns Hopkins
22%
Prostate-specific Antigen Response
22%
Epic
22%
Docetaxel
11%
Messenger RNA (mRNA)
11%
Prognostic Value
11%
Clinical Benefit
11%
Cabazitaxel
11%
Blinded Study
11%
Prostate-specific Antigen
11%
Non-associated
11%
Progression-free
11%
Poor Risk
11%
Clinical Prognostic Factors
11%
RNA Assay
11%
Protein Assay
11%
Cell Enumeration
11%
CellSearch
11%
Blood-based Assay
11%
Prophecy
11%
AdnaTest
11%
Agricultural and Biological Sciences
Receptor
100%
Taxane
100%
Androgen
100%
Malignant Neoplasm
100%
Neoplasm
100%
Tumor
100%
Enzalutamide
55%
Abiraterone
55%
Prostate-Specific Antigen
33%
Docetaxel
11%
Messenger RNA
11%
Pretreatment
11%
Medicine and Dentistry
Androgen Receptor
100%
Circulating Tumor Cell
100%
Castration Resistant Prostate Cancer
100%
Treatment Outcome
100%
Overall Survival
55%
Abiraterone
55%
Enzalutamide
55%
Hazard Ratio
44%
Prostate Specific Antigen
33%
Prognostic Factor
11%
Cell Counting
11%
Progression Free Survival
11%
Antigen Response
11%
Protein Determination
11%
Still's Disease
11%
Tumor Marker Rapid Test
11%
Docetaxel
11%
Cabazitaxel
11%
Messenger RNA
11%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Neoplasm
100%
Taxane
100%
Enzalutamide
55%
Abiraterone
55%
Overall Survival
55%
Chemotherapy
44%
Prostate Specific Antigen
33%
Docetaxel
11%
Cabazitaxel
11%
Progression Free Survival
11%
Messenger RNA
11%
Diseases
11%